Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer(WJOG10417GTR)

Trial Profile

A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer(WJOG10417GTR)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2023 Results of a biomarker analysis assessing LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer presented at the 2023 Gastrointestinal Cancers Symposium
    • 13 Sep 2022 Results (between August 2018 and November 2020) assessing the prognostic impact of these subsets remains to be determined, particularly in advanced gastric cancer patients receiving nivolumab monotherapy that provides limited efficacy, presented at the 47th European Society for Medical Oncology Congress.
    • 13 Sep 2022 Results (n=91) assessing profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer, presented at the 47th European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top